These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 8733770)
1. Immunohistochemical and molecular evaluation of the mdm-2 gene product in bronchogenic carcinoma. Gorgoulis VG; Rassidakis GZ; Karameris AM; Papastamatiou H; Trigidou R; Veslemes M; Rassidakis AN; Kittas C Mod Pathol; 1996 May; 9(5):544-54. PubMed ID: 8733770 [TBL] [Abstract][Full Text] [Related]
2. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions. Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708 [TBL] [Abstract][Full Text] [Related]
3. A molecular and immunohistochemical study of the MDM2 protein isoforms and p53 gene product in bronchogenic carcinoma. Gorgoulis VG; Zoumpourlis V; Rassidakis GZ; Karameris A; Rassidakis AN; Spandidos DA; Kittas C J Pathol; 1996 Oct; 180(2):129-37. PubMed ID: 8976869 [TBL] [Abstract][Full Text] [Related]
4. MDM-2 oncoprotein overexpression in laryngeal squamous cell carcinoma: association with wild-type p53 accumulation. Pruneri G; Pignataro L; Carboni N; Luminari S; Capaccio P; Neri A; Buffa R Mod Pathol; 1997 Aug; 10(8):785-92. PubMed ID: 9267820 [TBL] [Abstract][Full Text] [Related]
5. [The expression of Mdm2 protein and p53 mutation in lung squamous cell carcinomas and their clinicopathological significance]. Zhang J; Liu H; Li S; Gu C Zhonghua Jie He He Hu Xi Za Zhi; 1999 Mar; 22(3):163-5. PubMed ID: 11812371 [TBL] [Abstract][Full Text] [Related]
6. [Clinicopathological study on primary lung cancer--immunohistochemical expression of p53 suppressor gene and bcl-2 oncogene in relation to prognosis]. Irie K; Ishida H; Furukawa T; Koyanagi K; Miyamoto Y Rinsho Byori; 1996 Jan; 44(1):32-41. PubMed ID: 8691638 [TBL] [Abstract][Full Text] [Related]
7. mdm-2 expression correlates with wild-type p53 status in esophageal adenocarcinoma. Soslow RA; Altorki NK; Yang G; Xie D; Yang CS Mod Pathol; 1999 Jun; 12(6):580-6. PubMed ID: 10392633 [TBL] [Abstract][Full Text] [Related]
8. Alterations affecting the p53 control pathway in bilharzial-related bladder cancer. Osman I; Scher HI; Zhang ZF; Pellicer I; Hamza R; Eissa S; Khaled H; Cordon-Cardo C Clin Cancer Res; 1997 Apr; 3(4):531-6. PubMed ID: 9815716 [TBL] [Abstract][Full Text] [Related]
9. p53 apoptotic pathway molecules are frequently and simultaneously altered in nonsmall cell lung carcinoma. Mori S; Ito G; Usami N; Yoshioka H; Ueda Y; Kodama Y; Takahashi M; Fong KM; Shimokata K; Sekido Y Cancer; 2004 Apr; 100(8):1673-82. PubMed ID: 15073856 [TBL] [Abstract][Full Text] [Related]
10. Clinical relevance of immunohistochemical expression of p53-targeted gene products mdm-2, p21 and bcl-2 in breast carcinoma. Bánkfalvi A; Tory K; Kemper M; Breukelmann D; Cubick C; Poremba C; Füzesi L; Lellè RJ; Böcker W Pathol Res Pract; 2000; 196(7):489-501. PubMed ID: 10926327 [TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical detection of p53 in melanomas with rare p53 gene mutations is associated with mdm-2 overexpression. Poremba C; Yandell DW; Metze D; Kamanabrou D; Böcker W; Dockhorn-Dworniczak B Oncol Res; 1995; 7(7-8):331-9. PubMed ID: 8747596 [TBL] [Abstract][Full Text] [Related]
13. P53 and MDM2 co-expression in tobacco and betel chewing-associated oral squamous cell carcinomas. Shwe M; Chiguchi G; Yamada S; Nakajima T; Maung KK; Takagi M; Amagasa T; Tsuchida N J Med Dent Sci; 2001 Dec; 48(4):113-9. PubMed ID: 12160248 [TBL] [Abstract][Full Text] [Related]
14. Alterations in the p53 and MDM-2 genes are infrequent in clinically localized, stage B prostate adenocarcinomas. Ittmann M; Wieczorek R; Heller P; Dave A; Provet J; Krolewski J Am J Pathol; 1994 Aug; 145(2):287-93. PubMed ID: 8053489 [TBL] [Abstract][Full Text] [Related]
15. Altered expression of mdm-2 and its association with p53 protein status, tumor-cell-proliferation rate and prognosis in cervical neoplasia. Dellas A; Schultheiss E; Almendral AC; Gudat F; Oberholzer M; Feichter G; Moch H; Torhorst J Int J Cancer; 1997 Aug; 74(4):421-5. PubMed ID: 9291432 [TBL] [Abstract][Full Text] [Related]
16. Topoisomerase IIalpha gene expression is regulated by the p53 tumor suppressor gene in nonsmall cell lung carcinoma patients. Liu D; Huang CL; Kameyama K; Hayashi E; Yamauchi A; Sumitomo S; Yokomise H Cancer; 2002 Apr; 94(8):2239-47. PubMed ID: 12001123 [TBL] [Abstract][Full Text] [Related]
17. Heterogeneous distribution of P53 immunoreactivity in human lung adenocarcinoma correlates with MDM2 protein expression, rather than with P53 gene mutation. Koga T; Hashimoto S; Sugio K; Yoshino I; Nakagawa K; Yonemitsu Y; Sugimachi K; Sueishi K Int J Cancer; 2001 Jul; 95(4):232-9. PubMed ID: 11400116 [TBL] [Abstract][Full Text] [Related]